卡培他滨联合多西他赛对乳腺癌肝转移患者血管内皮生长因子、肝细胞生长因子及预后的影响

Effects of capecitabine and docetaxel on vascular endothelial growth factor,hepatocyte growth factor and prognosis in patients with liver metastasis of breast cancer

目的:探讨卡培他滨联合多西他赛对乳腺癌肝转移患者血管内皮生长因子、肝细胞生长因子的影响,分析其治疗可能作用机制。方法:收集2012年1月~2014年6月收治的乳腺癌肝转移患者216例为研究对象,随机分为观察组和对照组各108例,对照组给予多西他赛治疗,观察组给予卡培他滨联合多西他赛治疗,比较两组近期疗效、血管内皮生长因子、肝细胞生长因子、不良反应、生存率。结果:观察组疾病控制率88.89%明显高于对照组70.37%(χ~2=11.416,P<0.01);血管内皮生长因子VEGF-A、VEGF-C、VEGFR-3、肝细胞生长因子(HGF)明显低于对照组(t=14.684,16.726,16.733,4.508,P<0.05,P<0.01);两组不良反应比较差异无统计学意义(20.37%vs 26.85%)(χ~2=1.258,P>0.05);随访12个月、24个月、36个月,观察组生存率高于对照组,但差异无统计学意义(78.70%vs 70.37%,62.96%vs 55.56%,40.74%vs 30.56%)(χ~2=1.976,1.227,2.442,P>0.05)。结论:卡培他滨联合多西他赛治疗有助于提高临床疗效,且安全可靠,可能与降低患者血清血管内皮生长因子、肝细胞生长因子含量有关。

Objective：To investigate the effects of capecitabine and docetaxel on vascular endothelial growth factor and hepatocyte growth factor in patients with liver metastasis of breast cancer,and to analyze the possible mechanism of its treatment.Methods：A total of 216 patients with liver metastasis of breast cancer from January 2012 to June 2014 were enrolled,and the patients were randomly divided into observation group and control group with 108 cases in each group,and the control group was treated with docetaxel,and the observation group was treated with capecitabine combined with docetaxel.The short-term efficacy,vascular endothelial growth factor,hepatocyte growth factor,adverse reaction and survival rate were compared between the two groups.Results：The rate of disease control in the observation group was 88.89%,which was higher than that in the control group 70.37%（χ~2=11.416,P0.01）.Vascular endothelial growth factor VEGF-A,VEGF-C,VEGFR-3 and hepatocyte growth factor（HGF） were significantly lower than those in the control group（t=14.684,16.726,16.733,4.508,P0.05,P0.01）.There was no significant difference in adverse reactions between the two groups（20.37% vs 26.85%）（χ~2=1.258,P0.05）.After the patients were followed up for 12 months,24 months,and 36 months,the survival rate of the observation group was higher than that of the control group,but the difference was not statistically significant（78.70% vs 70.37%,62.96% vs 55.56%,40.74% vs 30.56%）（χ~2=1.976,1.227,2.442,P0.05）.Conclusion：Capecitabine combined with docetaxel treatment is helpful to improve the clinical efficacy,and safe and reliable.It may be related to the decrease of serum vascular endothelial growth factor and hepatocyte growth factor in patients.